ImmunoPrecise Antibodies Partners with RIBOPRO to Advance AI-Driven Antibody Discovery

• ImmunoPrecise Antibodies Ltd. has entered a strategic collaboration with RIBOPRO, a specialist in mRNA and lipid nanoparticle (LNP) technologies.

• The partnership aims to enhance therapeutic antibody discovery by integrating mRNA-based antigen expression with AI-powered discovery workflows.

ImmunoPrecise Antibodies Ltd. (IPA) has announced a collaboration with RIBOPRO to improve the discovery and development of therapeutic antibodies. The partnership will integrate RIBOPRO’s expertise in mRNA sequence optimisation and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and AI-driven discovery workflows.

Traditional immunisation-based antibody discovery methods often face challenges in antigen expression. By utilising RIBOPRO’s proprietary mRNA and LNP technologies, the collaboration aims to enhance antigen presentation and immune responses, potentially accelerating the development of novel therapeutics.

Sander van Asbeck, CEO of RIBOPRO, stated, “Partnering with ImmunoPrecise Antibodies enables us to push the boundaries of mRNA-based immunisation for therapeutic antibody discovery.” He emphasised that combining mRNA design and nanoparticle delivery with IPA’s advanced antibody discovery capabilities could lead to new possibilities for precision therapeutics.

The integration of mRNA immunisation into IPA’s workflow is expected to improve the precision and efficiency of its antibody discovery pipeline. Dr. Ilse Roodink, CSO of ImmunoPrecise Antibodies, highlighted that this alliance strengthens their commitment to addressing complex challenges with innovative solutions.